N
NVO

Natixis’s Novo Nordisk NVO Stock Holding History

Natixis’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.5M Sell
824,229
-1,181,056
-59% -$50.7M 0.16% 91
2026
Q1 		$73.7M Buy
2,005,285
+1,159,987
+137% +$55M 0.26% 51
2025
Q4 		$43M Buy
845,298
+462,211
+121% +$23.6M 0.15% 94
2025
Q3 		$21.3M Buy
383,087
+354,425
+1,237% +$20.7M 0.1% 180
2025
Q2 		$1.98M Buy
28,662
+3,745
+15% +$255K 0.01% 492
2025
Q1 		$1.71M Sell
24,917
-2,881
-10% -$238K 0.01% 465
2024
Q4 		$2.39M Buy
27,798
+25,192
+967% +$2.72M 0.01% 438
2024
Q3 		$310K Buy
2,606
+2,420
+1,301% +$323K ﹤0.01% 679
2024
Q2 		$26.6K Sell
186
-5,717
-97% -$758K ﹤0.01% 809
2024
Q1 		$758K Buy
5,903
+5,207
+748% +$620K ﹤0.01% 565
2023
Q4 		$72K Sell
696
-803
-54% -$79.4K ﹤0.01% 799
2023
Q3 		$136K Buy
+1,499
New +$132K ﹤0.01% 756
2022
Q2 		– Sell
-3,798
Closed -$211K – 1292
2022
Q1 		$211K Buy
3,798
+90
+2% +$4.62K ﹤0.01% 1106
2021
Q4 		$208K Buy
+3,708
New +$201K ﹤0.01% 1172
2019
Q2 		– Sell
-24,140
Closed -$628K – 856
2019
Q1 		$628K Buy
24,140
+5,092
+27% +$125K ﹤0.01% 644
2018
Q4 		$439K Sell
19,048
-396
-2% -$8.8K ﹤0.01% 592
2018
Q3 		$458K Buy
19,444
+5,526
+40% +$135K ﹤0.01% 641
2018
Q2 		$321K Buy
13,918
+5,326
+62% +$127K ﹤0.01% 752
2018
Q1 		$212K Buy
8,592
+476
+6% +$12.5K ﹤0.01% 834
2017
Q4 		$218K Buy
+8,116
New +$206K ﹤0.01% 772
2017
Q3 		– Sell
-18,430
Closed -$395K – 1331
2017
Q2 		$395K Sell
18,430
-27,082
-60% -$546K ﹤0.01% 570
2017
Q1 		$780K Buy
45,512
+7,522
+20% +$131K 0.01% 433
2016
Q4 		$681K Buy
37,990
+16,850
+80% +$305K 0.01% 496
2016
Q3 		$440K Buy
21,140
+7,722
+58% +$191K 0.01% 446
2016
Q2 		$361K Buy
+13,418
New +$368K 0.01% 349

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Natixis's NVO Position: Q2 2026 in Review

Natixis reduced its Novo Nordisk (NVO) stake by 59% in Q2 2026, selling an estimated $50.7M and leaving 824,229 shares worth $39.5M. The position accounts for 0.16% of the portfolio, ranked #91.

Natixis first reported a position in NVO in Q2 2016 and has held it in 25 quarters since. The position peaked at $73.7M in Q1 2026. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Natixis held 824,229 shares of Novo Nordisk worth $39.5M as of Q2 2026.
  • Natixis sold 1,181,056 Novo Nordisk shares in Q2 2026, an estimated $50.7M.
  • Novo Nordisk made up 0.16% of Natixis's portfolio in Q2 2026, its #91 holding.
  • Natixis first reported a position in Novo Nordisk in Q2 2016 and has held it in 25 quarters since.
  • Natixis's Novo Nordisk position peaked at $73.7M in Q1 2026.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.